Clinical Trial Update: Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing trastuzumab in stage III/IV or recurrent endometrial cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, ERBB2 Gene Amplification | Phase 2 | Status: COMPLETED